Prosecution Insights
Last updated: April 19, 2026

Curevac AG

6 pending office actions

Portfolio Summary

6
Total Pending OAs
3
Final Rejections
3
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
17634958 RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES SHIN, DANA H 1635 Final Rejection Feb 11, 2022
17576583 ARTIFICIAL NUCLEIC ACID MOLECULES LEITH, NANCY J 1636 Non-Final OA Jan 14, 2022
17620047 ROTAVIRUS MRNA VACCINE GRABER, JAMES J 1631 Final Rejection Dec 16, 2021
17429182 CODING RNA ADMINISTERED INTO THE SUPRACHOROIDAL SPACE IN THE TREATMENT OF OPHTHALMIC DISEASES FAY, ZOHREH ALEMZADEH 1617 Non-Final OA Aug 06, 2021
17378954 COMPOSITION FOR TREATING LUNG CANCER, PARTICULARLY OF NON-SMALL LUNG CANCERS (NSCLC) WILSON, MICHAEL C 1638 Final Rejection Jul 19, 2021
17045236 NOVEL YELLOW FEVER NUCLEIC ACID MOLECULES FOR VACCINATION VYAS, KEYUR ANILKUMAR 1637 Non-Final OA Oct 05, 2020

Managing Curevac AG's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month